Provectus Biopharmaceuticals annual return on equity
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Provectus Biopharmaceuticals Return on Equity (ROE) Growth & History (PVCT)
Provectus Biopharmaceuticals's return on equity was −246.91% for fiscal 2016.
View full Provectus Biopharmaceuticals company overviewProvectus Biopharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2016 | 2016-12-31 | −246.91% | −128.85 pp |
| 2015 | 2015-12-31 | −118.06% | −53.68 pp |
| 2014 | 2014-12-31 | −64.38% | +438.20 pp |
| 2013 | 2013-12-31 | −502.58% | −328.18 pp |
| 2012 | 2012-12-31 | −174.40% | +13.20 pp |
| 2011 | 2011-12-31 | −187.60% | −3.06 pp |
| 2010 | 2010-12-31 | −184.54% | −57.91 pp |
| 2009 | 2009-12-31 | −126.63% | −44.10 pp |
| 2008 | 2008-12-31 | −82.53% | −16.60 pp |
| 2007 | 2007-12-31 | −65.93% | −6.61 pp |
| 2006 | 2006-12-31 | −59.32% | +40.59 pp |
| 2005 | 2005-12-31 | −99.91% | −55.15 pp |
| 2004 | 2004-12-31 | −44.76% | −16.04 pp |
| 2003 | 2003-12-31 | −28.72% | — |
Provectus Biopharmaceuticals quarterly return on equity
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2017 | 2017-03-31 | −344.43% | −288.65 pp |
| Q4 2016 | 2016-12-31 | −113.93% | −66.67 pp |
| Q3 2016 | 2016-09-30 | −81.33% | −60.23 pp |
| Q2 2016 | 2016-06-30 | −43.25% | −25.75 pp |
| Q1 2016 | 2016-03-31 | −55.78% | −36.47 pp |
| Q4 2015 | 2015-12-31 | −47.26% | −50.91 pp |
| Q3 2015 | 2015-09-30 | −21.10% | −2.13 pp |
| Q2 2015 | 2015-06-30 | −17.50% | −13.77 pp |
| Q1 2015 | 2015-03-31 | −19.30% | +43.75 pp |
| Q4 2014 | 2014-12-31 | 3.65% | +219.88 pp |
| Q3 2014 | 2014-09-30 | −18.97% | +41.45 pp |
| Q2 2014 | 2014-06-30 | −3.73% | +36.56 pp |
| Q1 2014 | 2014-03-31 | −63.05% | +21.62 pp |
| Q4 2013 | 2013-12-31 | −216.23% | −167.09 pp |
| Q3 2013 | 2013-09-30 | −60.42% | −3.79 pp |
| Q2 2013 | 2013-06-30 | −40.29% | +29.07 pp |
| Q1 2013 | 2013-03-31 | −84.67% | −29.53 pp |
| Q4 2012 | 2012-12-31 | −49.15% | −18.02 pp |
| Q3 2012 | 2012-09-30 | −56.63% | −8.80 pp |
| Q2 2012 | 2012-06-30 | −69.36% | −33.76 pp |
| Q1 2012 | 2012-03-31 | −55.13% | — |
| Q4 2011 | 2011-12-31 | −31.13% | — |
| Q3 2011 | 2011-09-30 | −47.83% | — |
| Q2 2011 | 2011-06-30 | −35.60% | — |
Provectus Biopharmaceuticals return on equity trends
Over the last five fiscal years, Provectus Biopharmaceuticals's return on equity decreased from −187.60% to −246.91%, a change of −59.31 percentage points. The latest reported quarter, Q1 2017, shows −344.43%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Provectus Biopharmaceuticals source filings ↗